---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000057"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:31:57.197157+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote

## Summary
- Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.
- Licensed sotagliflozin to Viatris for ex-U.S./Europe markets; $25M upfront, up to $197M milestones.
- ZYNQUISTA AdCom voted 11-3 that benefits do not outweigh risks; PDUFA target Dec 20, 2024.
- INPEFA net sales $1.7M; field force reduced ~50% in September to focus on targeted prescribers.
- LX9211 Phase 2b DPNP screening complete, topline data now expected Q1 2025; LX9851 IND on track mid-2025.

## SEC filing metadata
- accession: 0001062822-24-000057
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/0001062822-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/lxrx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000057
- JSON: https://secwatch.observer/filing/0001062822-24-000057.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.